lymphoproliferative disorder

lymphoproliferative disorder

Oncology Any clonal expansion of lymphatic system cells–eg, clearly malignant conditions–eg, leukemia, lymphoma, Hodgkin's disease and relatively indolent lesions–eg, lymphomatoid granulomatosis and lymphomatoid papulosis
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
An abnormally high [CD4.sup.+] count was detected on follow-up in September 2002 prompting T-cell receptor polymerase chain reaction (PCR) studies, which revealed no evidence of a clonal T-cell lymphoproliferative disorder. A bone marrow biopsy was also performed and showed non-malignant T-cell hyperplasia.
Preiksaitis, "Epstein-Barr virus and post-transplant lymphoproliferative disorder in solid organ transplant recipients," American Journal of Transplantation, vol.
Her family history was negative for lymphoproliferative disorder and amyloidosis.
Multicentric Castleman's disease (MCD) is an uncommon lymphoproliferative disorder that presents with fevers, anaemia and multifocal lymphadenopathy, and nowadays it is most commonly diagnosed in individuals infected with human immunodeficiency virus type-1 (HIV).
Posttransplantation lymphoproliferative disorder (PTLD) complicates 2% to 8.4% of adult liver transplants.
* Those also occurring in other immunodeficiency states such as post-transplant lymphoproliferative disorder. (11)
Post-transplant lymphoproliferative disorder (PTLD) can be attributed to an acute infection with EBV following transplantation.
SAN FRANCISCO -- Consider tonsillectomy and adenoidectomy for children with posttransplant lymphoproliferative disorder, for both therapeutic and diagnostic reasons, Dr.
Burnett adds that while his caution for the company's MS program is in line with consensus view, he believes the Street is "missing" that success in post-transplant lymphoproliferative disorder study would "validate" its HLA approach.
The United States Food and Drug Administration (FDA) has granted Orphan Drug Designations (ODD) to United States-based Viracta Therapeutics, Incorporated's Phase two drug candidate, nanatinostat, in combination with the antiviral valganciclovir intended for the treatment of post-transplant lymphoproliferative disorder (PTLD), plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma, it was reported yesterday.